{"protocolSection":{"identificationModule":{"nctId":"NCT05038228","orgStudyIdInfo":{"id":"B0661161"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","officialTitle":"Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database","acronym":"HELIOS-AF"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-08-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-08-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-08-31","studyFirstSubmitQcDate":"2021-08-31","studyFirstPostDateStruct":{"date":"2021-09-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-15","lastUpdatePostDateStruct":{"date":"2023-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF with high risk of gastrointestinal bleed who initiate anticoagulant treatment with a Vitamin-K Antagonists (VKAs) or direct-acting oral anticoagulants (DOACs)."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Eliquis","Anti-Coagulation","Bleed","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":1,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NVAF High GI bleed risk","description":"NVAF patients with a high risk of gastrointestinal bleeding","interventionNames":["Drug: Apixaban","Drug: Rivaroxaban","Drug: Dabigatran","Drug: Vitamin K antagonist (VKA)"]}],"interventions":[{"type":"DRUG","name":"Apixaban","description":"Anticoagulant","armGroupLabels":["NVAF High GI bleed risk"]},{"type":"DRUG","name":"Rivaroxaban","description":"Anticoagulant","armGroupLabels":["NVAF High GI bleed risk"]},{"type":"DRUG","name":"Dabigatran","description":"Anticoagulant","armGroupLabels":["NVAF High GI bleed risk"]},{"type":"DRUG","name":"Vitamin K antagonist (VKA)","description":"Anticoagulant","armGroupLabels":["NVAF High GI bleed risk"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Bleeding leading to hospitalization","description":"The follow-up period will be from the index date to death or end of study (31 December 2019). For the comparative analyses of clinical outcomes the follow-up period will be from the day after index date to the earliest of an outcome of interest (separately for each outcome); treatment discontinuation, treatment switch, death, or end of study.","timeFrame":"2016-2019"},{"measure":"Stroke","description":"The follow-up period will be from the index date to death or end of study (31 December 2019). For the comparative analyses of clinical outcomes the follow-up period will be from the index date to the earliest of an outcome of interest (separately for each outcome); treatment discontinuation, treatment switch, death, or end of study.","timeFrame":"2016-2019"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients covered by the French national health insurance general scheme With at least one reimbursement of AC treatment (apixaban, rivaroxaban, dabigatran, or VKAs) Aged â‰¥18 years as of the index date With a diagnosis of atrial fibrillation (AF) prior to or on the index date With at least one risk factor for gastrointestinal bleeding\n\nExclusion Criteria:\n\nPatients with different types of AC treatment at the index date Patients with a diagnosis or procedure code indicative of rheumatic mitral valvular heart disease or valve replacement procedure Individuals with a diagnosis of VTE during the 12 months prior to or on the index date","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Adult patients with a diagnosis of non-valvular atrial fibrillation being treated with anticoagulation.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigator","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=B0661161"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9247","name":"Gastrointestinal Hemorrhage","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069552","term":"Rivaroxaban"},{"id":"C000522181","term":"Apixaban"},{"id":"D000069604","term":"Dabigatran"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}